Dexcom Archives - Page 8 of 14 - Medical Design Sourcing

The biggest stories from the American Diabetes Association (ADA) 2022 Scientific Sessions

For the 82nd time, the American Diabetes Association (ADA) Scientific Sessions convened to highlight all the innovations within the diabetes technology space.

Major players like Dexcom, Medtronic, Abbott and more continue to plug along, while companies like Bigfoot Biomedical, One Drop and others shared data backing the technology that they bring to the table.

The data showcased at ADA supported the usual continuous glucose monitoring (CGM) and automated insulin delivery (AID) technology, plus different digital health platforms and diabetes reversal procedures.

BTIG analyst Marie Thibault wrote in a report that there was plenty of buzz on the ground at the event, particularly around Insulet’s Omnipod 5 AID system, Abbott’s recently FDA-cleared FreeStyle Libre 3 CGM and Bigfoot Biomedical’s Bigfoot Unity platform.

“In general, we believe that accuracy and clinical benefit is proven for all commercial CGM and AID offerings an…

Dexcom CEO expects ‘science boom’ with CGM, automated insulin delivery

[Image from Dexcom] With the G7 nearing FDA clearance, Dexcom leadership foresees major innovations for integrated automated insulin delivery down the line.

Kevin Sayer began thinking about automated insulin delivery all the way back in 1994 when he was working at MiniMed. Nearly 30 years later, as CEO of Dexcom (Nasdaq:DXCM), that space continues to pique his interest.

In the 90s, MiniMed ran trials with a fully implantable system before Medtronic bought the company. Sayer admits the system with an implantable pump and sensor wasn’t particularly practical, but it planted the seeds for what could grow.

Now with Dexcom, the maker of the leading G6 continuous glucose monitoring (CGM) system — and the next-generation G7, which is expected to receive FDA clearance soon — Sayer has seen the integration of CGM with automated insulin delivery through partnerships with Insulet and Tandem Diabetes Care and he believes that, with pump penetration not yet passing 50% of i…

Dexcom quashes talk of Insulet merger, says discussions are not ongoing

Dexcom (Nasdaq:DXCM) has today issued a statement denying recent rumors of a potential merger with Insulet (Nasdaq:PODD).

Last week, reports circulated saying talks over a potential acquisition were ongoing with an agreement between the two diabetes technology developers on the horizon in the coming weeks.

On the back of the Dexcom statement, DXCM shares were up 7% at $308.87 per share as the market opened today. Conversely, PODD shares sank 11% to $209.65.

Get the full story at our sister site, Drug Delivery Business News.

Report: Dexcom in talks to acquire Insulet

Major players in the diabetes space could join forces as Dexcom (Nasdaq:DXCM) is reportedly in discussions to acquire Insulet (Nasdaq:PODD).

Bloomberg reported today that people “with knowledge of the matter” have said talks are ongoing over a potential acquisition and even said an agreement could be reached “in the coming weeks.” Bloomberg’s sources preferred to remain anonymous because the information is private and both companies declined to offer comment, the news outlet said.

Get the full story at our sister site, Drug Delivery Business News.

How Dexcom’s portfolio goes beyond highly-anticipated next-gen G7

The Dexcom One platform. [Image from Dexcom]

A lot of talk around Dexcom (Nasdaq:DXCM) in the last couple of years has centered around its next-generation G7 continuous glucose monitor.

The latest iteration of the company’s CGM platform has already garnered CE mark this year and awaits FDA approval, with some expectations for that to come after the American Diabetes Association’s Scientific Sessions next month. The company also presented new data highlighting the accuracy the G7 in children at last month’s Advanced Technologies & Treatments for Diabetes (ATTD) conference.

Dexcom Chief Technology Officer Jake Leach recently told Drug Delivery Business News that, while the excitement around G7 remains, that’s far from the only thing the San Diego-based company has to offer.

Get the full story at our sister site, Drug Delivery Business News.

How Dexcom’s portfolio goes beyond highly-anticipated next-gen G7

The Dexcom One platform. [Image from Dexcom]A lot of talk around Dexcom (Nasdaq:DXCM) in the last couple of years has centered around its next-generation G7 continuous glucose monitor.

The latest iteration of the company’s CGM platform has already garnered CE mark this year and awaits FDA approval, with some expectations for that to come after the American Diabetes Association’s Scientific Sessions next month. The company also presented new data highlighting the accuracy the G7 in children at last month’s Advanced Technologies & Treatments for Diabetes (ATTD) conference.

Dexcom Chief Technology Officer Jake Leach recently told Drug Delivery Business News that, while the excitement around G7 remains, that’s far from the only thing the San Diego-based company has to offer.

Get the full story at our sister site, Drug Delivery Business News.

CGMs, insulin pumps and more: the biggest diabetes news to come out of ATTD 2022

All kinds of technologies were on display at the Advanced Technologies & Treatments for Diabetes (ATTD) conference in Barcelona last week.

From continuous glucose monitoring (CGM) to automated insulin delivery, with plenty in between, a number of companies shared positive data for their diabetes offerings.

Here are five of the biggest stories to come out of ATTD 2022:

Dexcom’s G7 is accurate in pediatric T1D patients

Dexcom (Nasdaq:DXCM) published new data highlighting the accuracy of the next-generation G7 continuous glucose monitor in children.

The study, published in the Journal of Diabetes and Scientific Technology, evaluated the G7 CGM in children and adolescents with type 1 diabetes. G7, which last month won CE mark approval, remains under FDA 510(k) review.

Get the full story at our sister site, Drug Delivery Business News.

Dexcom study shows strong accuracy for next-gen G7 CGM in pediatric T1D patients

[Image from Dexcom]Dexcom (Nasdaq:DXCM) published new data highlighting the accuracy of the next-generation G7 continuous glucose monitor in children.

San Diego-based Dexcom’s study, published in the Journal of Diabetes and Scientific Technology, evaluated the G7 CGM in children and adolescents with type 1 diabetes. G7, which last month won CE mark approval, remains under FDA 510(k) review.

Get the full story at our sister site, Drug Delivery Business News.

Dexcom dips after hours on Q1 EPS miss

Dexcom (Nasdaq:DXCM) shares took a hit after hours today on first-quarter results that fell short of the consensus earnings forecast.

DXCM shares were down 6.2% at $387.61 per share after the market closed. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — closed the day down 0.3%.

Get the full story at our sister site, Drug Delivery Business News.

Welldoc says CGM, digital health platform combination provides better glycemic outcomes

Welldoc said that its combination of real-time continuous glucose monitoring (CGM) and digital health impacts glucose control in type 2 diabetes.

Columbia, Maryland-based Welldoc presented data at the Conference on Advanced Technologies & Treatments for Diabetes (ATTD) from a study of real-time CGM and digital health in individuals with type 2 diabetes not treated with insulin. For all participants and subgroups examines, time in range and the glucose management indicator (GMI) improved significantly, demonstrating that the combination could improve type 2 diabetes management and glycemic control.

Get the full story at our sister site, Drug Delivery Business News.

Dexcom announces availability of G6 for Tricare members as formulary pharmacy benefit

The Dexcom G6 continuous glucose monitor [Photo courtesy of Dexxom]Dexcom (Nasdaq:DXCM) announced that its G6 continuous glucose monitoring (CGM) system will be available through Tricare.

San Diego-based Dexcom’s CGM will be more easily available to military members, their families and retirees with diabetes as a Tricare brand-name formulary pharmacy benefit.

Get the full story at our sister site, Drug Delivery Business News.

Dexcom launches Dexcom One CGM in the UK

The Dexcom One platform. [Image from Dexcom]Dexcom (NSDQ:DXCM) announced today that it launched the new Dexcom One continuous glucose monitoring (CGM) system in the United Kingdom.

San Diego-based Dexcom designed the Dexcom One system as an easy-to-use, real-time CGM (rt-CGM) that it aims to make more affordable and accessible for people with diabetes in the UK.

Get the full story at our sister site, Drug Delivery Business News.